Regulatory landscape for cryopreserved apheresis products

The purpose of this BioPhorum member only survey is to understand what the industry current understanding of the FDA approach to fresh versus  cryopreserved apheresis as a starting material for autologous/allogenic cell therapy programs. The results of this survey are available to BioPhorum members only.

 

 

This document is reserved for the use of BioPhorum members only.

I don't have access to this document

Make a selection below and submit your request. We will get back to you ASAP.

My company would like to become a member

If you're not sure if your company is a member of this Phorum, or if you would like to enquire on behalf of your company about becoming a member, please see our membership page.